

SOCRA CCRP Practice Exam (Sample)

Study Guide



Everything you need from our exam experts!

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright	1
Table of Contents	2
Introduction	3
How to Use This Guide	4
Questions	5
Answers	8
Explanations	10
Next Steps	15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 - 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

SAMPLE

1. What is an in-vitro diagnostic?

- A. Type of medical device**
- B. A test performed inside the human body**
- C. A test performed outside the human body**
- D. A regulatory body**

2. What is an investigator's responsibility during study visits?

- A. Only to assess subjects' response to treatment**
- B. Only to evaluate subjects' compliance**
- C. Only to provide or oversee trial-related procedures**
- D. All of the above**

3. What are IND safety reports intended to communicate?

- A. Financial risks associated with the IP**
- B. Possible patent infringements by the IP**
- C. Potential serious risks associated with the IP**
- D. Pricing strategies for the IP on the market**

4. Who reviews a Significant Risk device study first?

- A. FDA**
- B. IRB**
- C. Sponsor/investigator**
- D. Department of Health**

5. Who is ultimately responsible for a clinical trial being conducted according to regulations?

- A. The principal investigator only**
- B. The FDA**
- C. The ethics committee**
- D. Sponsor or sponsor-investigator via Clinical Trial Monitor or CRA**

6. Which principle is NOT part of the Belmont Report?

- A. Respect for Persons**
- B. Beneficence**
- C. Justice**
- D. Equality**

7. What is the medical device equivalent of an SAE?

- A. Calibrated Device Incident**
- B. Unanticipated Adverse Device Effect (UADE)**
- C. Predicted Device Dysfunction**
- D. Calibrated Device Effectiveness**

8. Which of the following is not one of the seven recommendations for electronic document systems?

- A. Ensure systems document data changes**
- B. Allow unrestricted access to data for all employees**
- C. Maintain security system that prevents unauthorized access**
- D. Maintain list of individuals authorized to make data changes**

9. What principle ensures that research subjects are treated as autonomous agents?

- A. Respect for Persons**
- B. Beneficence**
- C. Justice**
- D. Equality and Diversity**

10. What FDA regulations govern UADE reporting?

- A. 21 CFR 101**
- B. 21 CFR 812**
- C. 42 CFR 483**
- D. 30 CFR 250**

Answers

SAMPLE

1. C
2. D
3. C
4. A
5. D
6. D
7. B
8. B
9. A
10. B

SAMPLE

Explanations

SAMPLE

1. What is an in-vitro diagnostic?

- A. Type of medical device**
- B. A test performed inside the human body**
- C. A test performed outside the human body**
- D. A regulatory body**

An in-vitro diagnostic is a test that is performed outside of the human body. Option A is incorrect because while an in-vitro diagnostic may include a type of medical device, not all medical devices are considered in-vitro diagnostics. Option B is incorrect because a test performed inside the human body would be considered an in-vivo diagnostic. Option D is incorrect because a regulatory body is an organization responsible for creating and enforcing regulations, not a type of diagnostic. Thus, option C is the most accurate and relevant choice.

2. What is an investigator's responsibility during study visits?

- A. Only to assess subjects' response to treatment**
- B. Only to evaluate subjects' compliance**
- C. Only to provide or oversee trial-related procedures**
- D. All of the above**

An investigator's responsibility during study visits includes all of the above options, not just one specific task. This is because the investigator serves as the main point of contact between the subject and the study, and is responsible for overseeing and managing the entire study process. Choosing only one of the options would limit the investigator's role and potentially result in incomplete or inaccurate data.

3. What are IND safety reports intended to communicate?

- A. Financial risks associated with the IP**
- B. Possible patent infringements by the IP**
- C. Potential serious risks associated with the IP**
- D. Pricing strategies for the IP on the market**

IND safety reports are intended to communicate potential serious risks associated with the investigational product (IP). It is important for these reports to clearly and accurately communicate any potential risks to ensure the safety of both participants in the clinical trial and future patients. Option A is incorrect because IND safety reports do not typically address financial risks associated with the IP. Option B is incorrect because intellectual property (IP) relates to patents and trademarks, but does not pertain to the safety of the product. Option D is incorrect because IND safety reports focus on potential safety risks, not pricing strategies for the IP on the market.

4. Who reviews a Significant Risk device study first?

- A. FDA**
- B. IRB**
- C. Sponsor/investigator**
- D. Department of Health**

The other options are incorrect because they are not responsible for reviewing Significant Risk device studies. B IRB, or Institutional Review Board, is responsible for reviewing studies that involve human participants to ensure ethical standards are met. C: Sponsor/investigator may be responsible for conducting the study, but not reviewing it. D: Department of Health may regulate medical devices but does not review studies. The FDA, or Food and Drug Administration, is the regulatory body responsible for reviewing and approving medical device studies, particularly those classified as Significant Risk.

5. Who is ultimately responsible for a clinical trial being conducted according to regulations?

- A. The principal investigator only**
- B. The FDA**
- C. The ethics committee**
- D. Sponsor or sponsor-investigator via Clinical Trial Monitor or CRA**

The sponsor or sponsor-investigator is ultimately responsible for ensuring that the clinical trial is conducted according to regulations. While the principal investigator, FDA, and ethics committee play important roles in the trial, the sponsor or sponsor-investigator has the overall responsibility for overseeing and managing the trial. This includes ensuring that all aspects of the trial adhere to regulations and that the safety and well-being of participants is prioritized. Therefore, the other options (A, B, and C) are incorrect as they do not hold the same level of responsibility as the sponsor or sponsor-investigator.

6. Which principle is NOT part of the Belmont Report?

- A. Respect for Persons**
- B. Beneficence**
- C. Justice**
- D. Equality**

The Belmont Report is an ethical framework for conducting research on human subjects. It consists of three guiding principles Respect for Persons, Beneficence, and Justice. Respect for Persons refers to treating individuals as autonomous agents and protecting those with diminished autonomy. Beneficence is the principle of doing good and minimizing harm to individuals. Justice involves ensuring an equal distribution of benefits and burdens among research participants. The principle of Equality is not part of the Belmont Report, as it is not explicitly mentioned or included in the original document.

7. What is the medical device equivalent of an SAE?

- A. Calibrated Device Incident
- B. Unanticipated Adverse Device Effect (UADE)**
- C. Predicted Device Dysfunction
- D. Calibrated Device Effectiveness

An SAE stands for Serious Adverse Event, which is an incident, whether related to the device or not, that results in death, life-threatening injury, permanent impairment of a body function, or requires medical or surgical intervention to prevent serious harm. The medical device equivalent of this is a UADE, or Unanticipated Adverse Device Effect. This is an unexpected and unfavorable reaction caused by a medical device that may result in serious harm or death. A Calibrated Device Incident (A) refers to a malfunction or issue with a device that has been calibrated. Predicted Device Dysfunction (C) is a potential issue that has not yet occurred. Calibrated Device Effectiveness (D) is not an official medical device term and does not accurately describe an adverse event. Therefore, the most accurate and similar term to an SAE is a UADE (B).

8. Which of the following is not one of the seven recommendations for electronic document systems?

- A. Ensure systems document data changes
- B. Allow unrestricted access to data for all employees**
- C. Maintain security system that prevents unauthorized access
- D. Maintain list of individuals authorized to make data changes

The seven recommendations for electronic document systems include ensuring systems document data changes, maintaining a security system that prevents unauthorized access, and maintaining a list of individuals authorized to make data changes. Option B, which suggests allowing unrestricted access to data for all employees, goes against the recommendation for maintaining a secure system and controlling access to data. It can potentially compromise the integrity and security of the system and its data. Therefore, it is not considered as one of the seven recommendations.

9. What principle ensures that research subjects are treated as autonomous agents?

- A. Respect for Persons**
- B. Beneficence
- C. Justice
- D. Equality and Diversity

Respect for Persons is a principle that ensures that research subjects are treated as autonomous agents. This means that they are able to make their own decisions and are not coerced into participating in research. This principle recognizes the importance of respecting the autonomy and dignity of individuals. Although beneficence is also a key principle in research ethics, it focuses on the obligation to do no harm and maximize benefits for research subjects. Justice, on the other hand, pertains to the fair distribution of the burdens and benefits of research. Equality and diversity are important considerations in research but are not directly related to the principle of respecting individuals as autonomous agents.

10. What FDA regulations govern UADE reporting?

- A. 21 CFR 101**
- B. 21 CFR 812**
- C. 42 CFR 483**
- D. 30 CFR 250**

The correct answer is B 21 CFR 812. The UADE reporting regulations for medical devices are governed by the Food and Drug Administration (FDA) under 21 CFR 812. This specific section of the Code of Federal Regulations is dedicated to the requirements for Investigational Device Exemptions, including the reporting of Unanticipated Adverse Device Effects (UADEs). Therefore, options A, C, and D are incorrect because they refer to different sections of the Code of Federal Regulations that do not pertain to medical device reporting. Option A (21 CFR 101) relates to labeling and nutrient content claims for food products, option C (42 CFR 483) pertains to long-term care facilities, and option D (30 CFR 250) deals with offshore drilling and worker safety.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

<https://ccrpsocraexam.examzify.com>

We wish you the very best on your exam journey. You've got this!

SAMPLE